Latest Period
Q1 2026
Security Snapshot
Aktis Oncology, Inc. - Common Stock (AKTS) Institutional Ownership
CUSIP: 01021M104
13F Institutional Holders and Ownership History for Q1 2026
Institutions Reporting
69
Shares (Excl. Options)
34,711,746
Price
$17.89
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- AKTS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 34,711,746
- Total 13F value
- $620,991,731
- Portfolio coverage rank
- 0%
- Share change
- +33,615,947
- Value change
- +$601,387,886
- Number of holders
- 69
- Shares outstanding
- 53,432,253
- SEC-reported price per share
- $19.92
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AKTS - Aktis Oncology, Inc. - Common Stock is tracked under CUSIP 01021M104.
- 69 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q1 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 69 institutions filings for Q1 2026.
Security key
01021M104
Latest holder period
Q1 2026
13F holders
69
13D/G owners
2
CIK / CUSIP context first
Open Q1 2026 holders
AKTS full holder history
Aktis Oncology, Inc. SEC filings
Aktis Oncology, Inc. company facts
Aktis Oncology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 01021M104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
AKTS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| VV Manager II, LLC | 11% | 5,831,315 | Helen Kim | 12 Jan 2026 | ||||
| EcoR1 Capital, LLC | 9.1% | 4,862,335 | Oleg Nodelman | 12 Jan 2026 |
As of 31 Mar 2026, 69 institutional investors reported holding 34,711,746 shares of Aktis Oncology, Inc. - Common Stock (AKTS). This represents 65% of the company’s total 53,432,253 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
62%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MPM BIOIMPACT LLC | 9.1% | 4,835,872 | 6.7% | $86,513,750 | |
| EcoR1 Capital, LLC | 9% | 4,824,469 | 3.7% | $86,309,750 | |
| Blue Owl Capital Holdings LP | 5.9% | 3,161,348 | 15% | $56,556,516 | |
| WELLINGTON MANAGEMENT GROUP LLP | 4.3% | 2,317,044 | 0.01% | $41,451,917 | |
| T. Rowe Price Investment Management, Inc. | 4% | 2,123,812 | 0.03% | $37,995,000 | |
| BlackRock, Inc. | 4% | 2,112,127 | 0% | $37,785,952 | |
| RTW INVESTMENTS, LP | 3% | 1,592,043 | 0.28% | $28,481,649 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.9% | 1,564,196 | 0% | $27,985,000 | |
| RA CAPITAL MANAGEMENT, L.P. | 2.8% | 1,503,084 | 0.28% | $26,890,173 | |
| JANUS HENDERSON GROUP PLC | 2.7% | 1,454,267 | 0.01% | $26,022,437 | |
| BAKER BROS. ADVISORS LP | 1.9% | 996,351 | 0.1% | $17,824,719 | |
| Octagon Capital Advisors LP | 1.8% | 960,847 | 1.9% | $17,189,553 | |
| Merck & Co., Inc. | 1.8% | 952,844 | 4.9% | $17,046,379 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.6% | 833,913 | 0% | 0% | $14,918,704 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.95% | 507,000 | 0.15% | $9,070,230 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 491,936 | 0% | $8,803,406 | |
| Avidity Partners Management LP | 0.88% | 468,566 | 1.7% | $8,382,646 | |
| STATE STREET CORP | 0.8% | 428,253 | 0% | $7,661,446 | |
| a16z Capital Management, L.L.C. | 0.78% | 415,000 | 0.58% | $7,424,350 | |
| FMR LLC | 0.72% | 386,379 | 0% | $6,912,320 | |
| UBS Group AG | 0.66% | 353,263 | 0% | $6,319,875 | |
| ArrowMark Colorado Holdings LLC | 0.62% | 329,471 | 0.16% | $5,894,236 | |
| Alyeska Investment Group, L.P. | 0.54% | 290,000 | 0.01% | $5,188,100 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.3% | 162,017 | 0% | $2,898,484 | |
| Driehaus Capital Management LLC | 0.28% | 150,000 | 0.02% | $2,683,500 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q1 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 34,711,746 | $620,991,731 | +$601,387,886 | $17.89 | 69 |